Cargando…

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

BACKGROUND: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. OBJECTIVE: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard AL, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720359/ https://www.ncbi.nlm.nih.gov/pubmed/31762387 http://dx.doi.org/10.1177/1352458519888610

Ejemplares similares

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
por: Okai, Annette F., et al.
Publicado: (2019)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
por: Hunter, Samuel F., et al.
Publicado: (2021)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
por: Barclay, Krista, et al.
Publicado: (2019)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis
por: Arroyo, Rafael, et al.
Publicado: (2019)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

Topaze : pièce en quatre actes
por: Pagnol, Marcel

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
por: Limmroth, Volker, et al.
Publicado: (2014)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
por: Coles, Alasdair J., et al.
Publicado: (2017)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

KEK: Testing TOPAZ
Publicado: (1985)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany
por: Balakrishnan, Preetha, et al.
Publicado: (2022)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

KEK : Essais de TOPAZ
Publicado: (1985)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
por: Steingo, Brian, et al.
Publicado: (2020)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rj96qni9rsqtfbvl8s914bfljr